Racivir

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Racivir
Racivir.svg
Systematic (IUPAC) name
4-amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one
Clinical data
Legal status
?
Routes Investigational
Identifiers
CAS number 137530-41-7
ATC code None
PubChem CID 454858
NIAID ChemDB 005245
Chemical data
Formula C8H10FN3O3S 
Mol. mass 247.25 g/mol

Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.[1] It is the enantiomer of emtricitabine, a widely-used NRTI, meaning that the two compounds are mirror images of each other.

Emtricitabine, the enantiomer of racivir and a widely-used NRTI


References[edit]

  1. ^ "Racivir". AIDSmeds.com. March 24, 2006. Retrieved March 21, 2008.